Skip to main content
. Author manuscript; available in PMC: 2018 Apr 29.
Published in final edited form as: Pharmacogenomics J. 2017 May 23;18(2):295–300. doi: 10.1038/tpj.2017.18

Figure 1. Association between the UGT2B17 CNV and urinary creatinine-adjusted 17β-DHE-Gluc, 17β-DHE and EXE levels in EXE-treated subjects.

Figure 1

Subjects were stratified by UGT2B17 CNV genotype, with the UGT2B17*1 allele corresponding to the wild-type single-gene copy number and the UGT2B17*2 allele corresponding to the UGT2B17 gene deletion variant. Panel A, UGT2B17 CNV genotypes versus creatinine-adjusted 17β-DHE-Gluc (nmol/mg creatinine); Panel B, UGT2B17 CNV genotypes versus creatinine-adjusted 17β-DHE; and Panel C, UGT2B17 CNV genotypes versus creatinine-adjusted EXE. All values are expressed as the median for 91 subjects.